AstraZeneca Pharma India Limited reported a strong start to FY2026-27, with total revenue from operations rising 30% year-on-year to ₹6,828 million in the first quarter ended June 30, 2026. The company said growth was supported by continued demand across its key therapy areas, including Oncology, Biopharmaceuticals covering cardiovascular, renal and respiratory diseases, and Rare Disease. The quarter also saw regulatory approvals for key medicines, new healthcare partnerships and initiatives aimed at improving diagnosis and access to treatment.
Bhavana Agrawal, Chief Financial Officer and Director, AstraZeneca Pharma India, said the company’s first-quarter performance builds on its track record of double-digit growth over the past five years. She added that the company remains focused on investing in opportunities that can support long-term growth and value creation.
Praveen Rao Akkinepally, Country President and Managing Director, AstraZeneca Pharma India, said the company’s performance reflects the strength of its portfolio and its focus on reaching more patients in India with innovative medicines. During the quarter, AstraZeneca received regulatory approval for acalabrutinib in combination with venetoclax, with or without obinutuzumab, for previously untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma.
The company also received approval for acalabrutinib with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are not eligible for autologous stem cell transplant. Another major regulatory milestone was the approval of trastuzumab deruxtecan in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
AstraZeneca also expanded its healthcare initiatives during the quarter. The company signed an MoU with the Government of Telangana to introduce AI-based lung cancer screening across 20 public healthcare facilities in urban and rural areas. The programme will use Qure.ai’s AI-powered chest X-ray technology to help identify high-risk pulmonary nodules and other lung conditions, while also training healthcare professionals.
The company launched K+ Connect, a nationwide initiative focused on improving the identification and management of hyperkalaemia among patients with heart failure and chronic kidney disease. In cardiovascular care, AstraZeneca launched India Coronary Conquest 2026 with STEMI India. The clinician-led programme is designed to support advanced cardiovascular care through case-based learning and professional collaboration among interventional cardiologists.
AstraZeneca Pharma India also received recognition at the OPPI India Awards 2026 for its work in Rare Disease and its Hyperkalaemia and Kidney Care initiative. It also received a Gold Award at the ETHRWorld Employee Experience Awards 2026. AstraZeneca Pharma India is the listed operating company of AstraZeneca in India. It focuses on prescription medicines across Oncology, Biopharmaceuticals and Rare Disease and has more than 600 employees across the country.
